Patents by Inventor Erland Arning

Erland Arning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of tetrahydrobiopterin as a marker and a therapeutic agent for fabry disease
    Patent number: 8410101
    Abstract: Blood and tissue markers of the metabolic status, risk of health complications in Fabry disease patients and as a biomarker to follow the efficacy of treatment in animal models and patients with Fabry disease comprising tetrahydrobiopterin (BH4), precursors and metabolites of BH4, and other related co-factors is disclosed herein. The present invention further describes the use of BH4 therapy as a treatment option for Fabry disease to prevent, slow or reverses vascular cardiac and renal manifestations of Fabry disease.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: April 2, 2013
    Assignee: Baylor Research Institute
    Inventors: Raphael Schiffmann, Teodoro G. Bottiglieri, Erland Arning, David F. Moore
  • ANALYSIS OF TOTAL HOMOCYSTEINE AND METHYLMALONIC ACID IN PLASMA BY LC-MS/MS FROM A PLASMA SEPARATOR DEVICE (PSD)
    Publication number: 20120318971
    Abstract: The present invention provides a method of diagnosing multiple disorders and distinguishing there between using a plasma sample obtained from a plasma separator device and analyzing the plasma sample using an LC-MS/MS to detect at least two analyte levels in the plasma sample to diagnose one or more disorders.
    Type: Application
    Filed: June 13, 2012
    Publication date: December 20, 2012
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Teodoro G. Bottiglieri, Erland Arning
  • Use of Tetrahydrobiopterin as a Marker and a Therapeutic Agent for Fabry Disease
    Publication number: 20100260747
    Abstract: Blood and tissue markers of the metabolic status, risk of health complications in Fabry disease patients and as a biomarker to follow the efficacy of treatment in animal models and patients with Fabry disease comprising tetrahydrobiopterin (BH4), precursors and metabolites of BH4, and other related co-factors is disclosed herein. The present invention further describes the use of BH4 therapy as a treatment option for Fabry disease to prevent, slow or reverses vascular cardiac and renal manifestations of Fabry disease.
    Type: Application
    Filed: April 9, 2010
    Publication date: October 14, 2010
    Applicant: BAYLOR RESEARCH INSTITUTE
    Inventors: Raphael Schiffmann, Teodoro G. Bottiglieri, Erland Arning, David F. Moore